Sugi Predict

Sugi Predict / Compounds / SCHEMBL2942282

SCHEMBL2942282

SCHEMBL2942282

O=C(O)c1ccc(N2CCN(C(=O)c3ccccn3)CC2)nn1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 4/20 0.64
▸ HTT P42858 1/20 0.59
▸ ALDH1A1 P00352 7/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ SLC6A7 Q99884 1/20 0.50
▸ TSHR P16473 2/20 0.49
▸ LMNA P02545 2/20 0.48
▸ NAPRT Q6XQN6 1/20 0.47
▸ P4HTM Q9NXG6 1/20 0.47
▸ NAMPT P43490 1/20 0.47
▸ EPHX2 P34913 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL994567 0.85 ALDH1A1 (0.53) L3MBTL1ALDH1A1MAPK1SLC6A7TSHR
SCHEMBL936603 0.84 SLC6A7 (0.55) L3MBTL1ALDH1A1MAPK1SLC6A7LMNA
SCHEMBL935772 0.81 ALDH1A1 (0.52) L3MBTL1ALDH1A1TSHRLMNAKDM4E
SCHEMBL7943306 0.80 L3MBTL1 (1.00) L3MBTL1HTTALDH1A1LMNANAPRT
SCHEMBL936649 0.80 GNE (0.50) L3MBTL1HTTMAPK1TSHRLMNA
SCHEMBL939188 0.79 HSD17B10 (0.62) L3MBTL1ALDH1A1KDM4EKMT2AHPGD
SCHEMBL938368 0.79 SCD (0.53) ALDH1A1TSHRMEN1KMT2A
SCHEMBL937123 0.79 HTT (0.61) L3MBTL1HTTALDH1A1TSHRKDM4E
SCHEMBL1377471 0.79 SCD (0.69) —
SCHEMBL1461593 0.77 L3MBTL1 (0.86) L3MBTL1HTTALDH1A1LMNANAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056460-A1 COMBINATION OF ORGANIC COMPOUNDS ALI MOHAMMED A 2010-03-04 — — US claimed
CN-100558713-C Pyridazine derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2009-11-11 — — CN claimed
US-20090131447-A1 COMBINATION THERAPY XENON PHARMACEUTICALS INC. (CA) 2009-05-21 — — US claimed
CN-101203244-A Compositions of rennin inhibitor and insulin secernent or insulin sensitizer NOVARTIS AG (CH) 2008-06-18 — — CN claimed
CN-101163504-A Combination therapy XENON PHARMACEUTICALS INC (CA) 2008-04-16 — — CN claimed
EP-1907004-A2 COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER Novartis AG (CH) 2008-04-09 — — EP claimed
US-7335658-B2 Pyridazine derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2008-02-26 — — US claimed
JP-2007500717-A — — 2007-01-18 — — JP claimed
WO-2007005763-A2 COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER NOVARTIS AG (CH) 2007-01-11 — — WO claimed
CN-1829698-A Pyridazine derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2006-09-06 — — CN claimed
EP-1648874-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-04-26 — — EP claimed
US-20050065143-A1 Pyridazine derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-03-24 — — US claimed
WO-2005011655-A2 PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2005-02-10 — — WO claimed
CN-102600162-A Pyridazine derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC 2012-07-25 — — CN disclosed
CN-101980709-A Pyridazine derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC 2011-02-23 — — CN disclosed
US-7759348-B2 Pyridazine derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2010-07-20 — — US disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 — — US disclosed
WO-2007005763-A2 COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER NOVARTIS AG (CH) 2007-01-11 — — WO disclosed
CN-1829698-A Pyridazine derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC (CA) 2006-09-06 — — CN disclosed
WO-2006086445-A2 COMBINATION THERAPY XENON PHARMACEUTICALS INC. (CA) 2006-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065143-A1 Pyridazine derivatives and their use as therapeutic agents PRDX5, SNRPD3, SNRPD2 L3MBTL1 1067/4885HTT 2613/4885ALDH1A1 2432/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 L3MBTL1 3373/4885HTT 8/4885ALDH1A1 3898/4885
US-20100056460-A1 COMBINATION OF ORGANIC COMPOUNDS REN, IAPP, ACE L3MBTL1 4875/4885HTT 1688/4885ALDH1A1 2324/4885
US-20090131447-A1 COMBINATION THERAPY SCD, SCD5, ARG1 L3MBTL1 182/4885HTT 1989/4885ALDH1A1 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.